drugset
drugset / Trial / NCT05967351

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

NCT05967351 ↗

Phase 3 Enrolling by invitation 400 enrolled Sarepta Therapeutics, Inc. Hoffmann-La Roche · collab
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.

Timeline

Start
2023-09-27
Primary completion
2033-10-31
Completion
2033-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject delandistrogene moxeparvovec Gene therapy (AAV / viral vector) — —

Indications

Duchenne muscular dystrophy